Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$102.96 USD

102.96
5,405,872

+0.01 (0.01%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $102.92 -0.04 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

TECH Stock Might Rise Following the Leo Shipping Announcement

by Zacks Equity Research

Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.

Zacks Equity Research

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

by Zacks Equity Research

QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

Zacks Equity Research

Boston Scientific (BSX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Boston Scientific (BSX) stood at $95.52, denoting a +1.48% change from the preceding trading day.

Zacks Equity Research

GEHC Stock May Gain as Genesis Portfolio Expands Cloud Offerings

by Zacks Equity Research

GE HealthCare unveils Genesis, a cloud-based imaging portfolio designed to enhance healthcare efficiency, streamline data access, and drive digital transformation.

Zacks Equity Research

Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?

by Zacks Equity Research

BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Reasons to Hold TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

CAH Stock Up Nearly 7% This Year: Is Now the Time to Buy?

by Zacks Equity Research

CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.

Zacks Equity Research

Phibro Animal Health Stock Up 87.5% in a Year: What's Driving the Rise?

by Zacks Equity Research

PAHC stays on investors' radar due to its Animal Health business and potential in emerging markets.

Zacks Equity Research

Positive Trial Data on Evolut TAVR Likely to Support MDT Stock

by Zacks Equity Research

At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.

Zacks Equity Research

SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge

by Zacks Equity Research

The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL continues to gain from its robust product portfolio and strong segmental performance.

Zacks Equity Research

Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission

by Zacks Equity Research

STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.

Zacks Equity Research

VEEV Stock Gains Following Latest Availability of HCP Access Data

by Zacks Equity Research

Veeva Systems aims to provide immediate value for commercial operations and data analytics teams via CRM Pulse, which provides quarterly HCP access data.

Zacks Equity Research

Boston Scientific (BSX) Down 4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cooper Companies Q1 Earnings In Line, Revenues Miss, Stock Falls

by Zacks Equity Research

COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.

Zacks Equity Research

ALGN Stock Gains on Addition of Upgrades to the iTero Lumina Solutions

by Zacks Equity Research

Align Technology adds restorative capabilities to the iTero Lumina Solutions - the iTero Lumina intraoral scanner and the iTero Lumina Pro dental imaging system.

Zacks Equity Research

Is it Worth Adding ResMed Stock to Your Portfolio Now?

by Zacks Equity Research

Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.

Zacks Equity Research

FMS Stock Gains Following Stake Sale to Reduce Debt & Boost Profit

by Zacks Equity Research

Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.

Zacks Equity Research

Baxter Stock Likely to Gain Following the Introduction of Voalte Linq

by Zacks Equity Research

At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.

Zacks Equity Research

Reasons to Retain Envista Stock in Your Portfolio for Now

by Zacks Equity Research

NVST's impressive long-term growth initiatives appear promising. Yet, a leveraged balance sheet is worrisome.

Zacks Equity Research

Is Trending Stock Boston Scientific Corporation (BSX) a Buy Now?

by Zacks Equity Research

Boston Scientific (BSX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Should Labcorp Stock Stay in Your Portfolio Right Now?

by Zacks Equity Research

LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.

Zacks Equity Research

Boston Scientific (BSX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Boston Scientific (BSX) closed at $104.71 in the latest trading session, marking a +1.06% move from the prior day.

Zacks Equity Research

SYK Stock Declines Despite Steri-Shield Launch to Boost OR Portfolio

by Zacks Equity Research

Stryker launches Steri-Shield 8, a cutting-edge PPE system with enhanced fit, visibility and protection, reinforcing its leadership in medical safety.